IFNG and cancer: Therefore, it is plausible that the reductions in type I NKT cell numbers and IFN-γ productivity frequently seen in cancer patients [112,113,114,115,116,117,118] help to explain why Treg-targeted therapies have not been successful in patients, as type II NKT cells may remain largely unchecked and able to exert immunosuppressive effects.